Rhabdomyosarcoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Rhabdomyosarcoma – Pipeline Review, H1 2017’, provides an overview of the Rhabdomyosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma

The report reviews pipeline therapeutics for Rhabdomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rhabdomyosarcoma therapeutics and enlists all their major and minor projects

The report assesses Rhabdomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bellicum Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

CytRx Corp

EpiZyme Inc

Exelixis Inc

Iproteos SL

Ipsen SA

MacroGenics Inc

Novartis AG

Noxxon Pharma AG

Pfizer Inc

Shionogi & Co Ltd

Taiho Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Rhabdomyosarcoma - Overview 6

Rhabdomyosarcoma - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Rhabdomyosarcoma - Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 17

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Rhabdomyosarcoma - Companies Involved in Therapeutics Development 24

Bellicum Pharmaceuticals Inc 24

Boehringer Ingelheim GmbH 24

Bristol-Myers Squibb Company 25

Celgene Corp 25

CytRx Corp 26

EpiZyme Inc 26

Exelixis Inc 27

Iproteos SL 27

Ipsen SA 28

MacroGenics Inc 28

Novartis AG 29

Noxxon Pharma AG 29

Pfizer Inc 30

Shionogi & Co Ltd 30

Taiho Pharmaceutical Co Ltd 31

Rhabdomyosarcoma - Drug Profiles 32

afatinib dimaleate - Drug Profile 32

aldoxorubicin hydrochloride - Drug Profile 46

AT-69 - Drug Profile 61

axitinib - Drug Profile 62

cabozantinib s-malate - Drug Profile 68

Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 87

Cellular Immunotherapy for Oncology - Drug Profile 89

Cellular Immunotherapy to Target GD2 and CD56 for Solid Tumors - Drug Profile 91

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 92

Celyvir - Drug Profile 93

crizotinib - Drug Profile 94

enoblituzumab - Drug Profile 101

everolimus - Drug Profile 104

ipilimumab + nivolumab - Drug Profile 118

irinotecan hydrochloride - Drug Profile 123

MAL-3101 - Drug Profile 135

NOXS-93 - Drug Profile 136

NR-001 - Drug Profile 137

paclitaxel albumin bound - Drug Profile 138

pazopanib hydrochloride - Drug Profile 150

S-588410 - Drug Profile 158

Synthetic Peptides for Rhabdomyosarcoma - Drug Profile 160

TAS-4464 - Drug Profile 161

tazemetostat - Drug Profile 162

VIMO-001 - Drug Profile 171

Rhabdomyosarcoma - Dormant Projects 172

Rhabdomyosarcoma - Discontinued Products 173

Appendix 174

Methodology 174

Coverage 174

Secondary Research 174

Primary Research 174

Expert Panel Validation 174

Contact Us 174

Disclaimer 175

List of Tables

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Rhabdomyosarcoma – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Rhabdomyosarcoma – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Rhabdomyosarcoma – Pipeline by Bristol-Myers Squibb Company, H1 2017

Rhabdomyosarcoma – Pipeline by Celgene Corp, H1 2017

Rhabdomyosarcoma – Pipeline by CytRx Corp, H1 2017

Rhabdomyosarcoma – Pipeline by EpiZyme Inc, H1 2017

Rhabdomyosarcoma – Pipeline by Exelixis Inc, H1 2017

Rhabdomyosarcoma – Pipeline by Iproteos SL, H1 2017

Rhabdomyosarcoma – Pipeline by Ipsen SA, H1 2017

Rhabdomyosarcoma – Pipeline by MacroGenics Inc, H1 2017

Rhabdomyosarcoma – Pipeline by Novartis AG, H1 2017

Rhabdomyosarcoma – Pipeline by Noxxon Pharma AG, H1 2017

Rhabdomyosarcoma – Pipeline by Pfizer Inc, H1 2017

Rhabdomyosarcoma – Pipeline by Shionogi & Co Ltd, H1 2017

Rhabdomyosarcoma – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Rhabdomyosarcoma – Dormant Projects, H1 2017

Rhabdomyosarcoma – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Rhabdomyosarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports